We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    LIFE-BTK
Previous Study | Return to List | Next Study

LIFE-BTK Randomized Controlled Trial (LIFE-BTK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04227899
Recruitment Status : Recruiting
First Posted : January 14, 2020
Last Update Posted : May 19, 2022
Sponsor:
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
Pre-market clinical evaluation of the everolimus eluting Esprit™ BTK System for the planned treatment of narrowed infrapopliteal lesions.

Condition or disease Intervention/treatment Phase
Critical Limb Ischemia (CLI) Device: Esprit BTK Device Device: Percutaneous Transluminal Angioplasty (PTA) Device Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: LIFE-BTK (pivotaL Investigation of saFety and Efficacy of BRS Treatment-Below The Knee) Randomized Controlled Trial
Actual Study Start Date : August 18, 2020
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : March 2027

Arm Intervention/treatment
Experimental: Esprit BTK
Participants who receives Esprit BTK device will be included in this arm
Device: Esprit BTK Device
Participants will receive Esprit BTK Device

Active Comparator: Percutaneous Transluminal Angioplasty (PTA)
Participants who receives PTA treatment will be included in this arm
Device: Percutaneous Transluminal Angioplasty (PTA) Device
Participants will receive PTA treatment




Primary Outcome Measures :
  1. Primary Efficacy Endpoint: Composite of Limb Salvage and Primary Patency at 6 Months [ Time Frame: At 6 months ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  2. Primary Safety Endpoint: Freedom from MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 6 months (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion occurring within 6 months and POD includes peri-procedural (or peri-operative) death at 30-days.


Secondary Outcome Measures :
  1. Powered Secondary Endpoint: Composite of Limb Salvage and Primary Patency [ Time Frame: At 1 year ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  2. Number of Participants with Acute Procedure Success [ Time Frame: Immediately after the procedure ]
    Successful target lesion treatment is defined as final diameter stenosis < 30% with final number of run-off vessels equivalent to or greater than number of run-off vessels at pre-procedure, with no residual dissection NHLBI grade ≥ type C, and no transient or sustained angiographic complications (e.g. distal embolization, perforation, thrombosis). Achieved using balloons plus Esprit BTK in the treatment arm and balloons in the control arm. This is defined on a per lesion basis.

  3. Number of Participants with Device Success- for Esprit arm only [ Time Frame: During the procedure ]
    Device success is defined on a per device basis, as the achievement of successful delivery and deployment of the study device(s) at the intended target lesion and successful withdrawal of the delivery catheter.

  4. Number of Participants with Technical Success [ Time Frame: Immediately after the procedure ]
    Technical success is defined on a per lesion basis as the attainment of a final residual stenosis of < 30% at the intended target lesion(s) following use of the study device(s). Standard pre-dilatation catheters and post-dilatation catheters (if applicable) may be used. Bailout at lesion level does not impact technical success if the above criteria are met.

  5. Number of Participants with Clinical Success [ Time Frame: Within 2 days after the index procedure or at hospital discharge ]
    Clinical success is defined on a per patient basis, as the attainment of a final residual stenosis of < 30% using the study device(s) and/or any adjunctive device at all intended target lesion(s) without complications within 2 days after the index procedure or at hospital discharge, whichever is sooner.

  6. Number of Participants with Angiographic acute gain (in-segment) [ Time Frame: Immediately after the procedure ]
    Acute gain is defined as the difference between post- and preprocedural minimal lumen diameter (MLD).

  7. Number of Participants with Angiographic acute gain (in-device) [ Time Frame: Immediately after the procedure ]
    Acute gain is defined as the difference between post- and preprocedural minimal lumen diameter (MLD). Angiographic acute gain (in-device) will be assessed for Esprit arm only

  8. Composite of Limb Salvage and Primary Patency [ Time Frame: At 1 month ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  9. Composite of Limb Salvage and Primary Patency [ Time Frame: At 3 months ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  10. Composite of Limb Salvage and Primary Patency [ Time Frame: At 6 months ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  11. Composite of Limb Salvage and Primary Patency [ Time Frame: At 1 year ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  12. Composite of Limb Salvage and Primary Patency [ Time Frame: At 2 years ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  13. Composite of Limb Salvage and Primary Patency [ Time Frame: At 3 years ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  14. Composite of Limb Salvage and Primary Patency [ Time Frame: At 4 years ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  15. Composite of Limb Salvage and Primary Patency [ Time Frame: At 5 years ]
    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR). Primary patency ends at the first occurrence of one of the following: 100% total occlusion of the target vessel, clinically-driven target lesion revascularization, or above ankle amputation due to target lesion restenosis or occlusion.

  16. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 1 month (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion at 1 month and POD includes peri-procedural (or peri-operative) death at 30-days.

  17. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 3 months (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion occurring within 3 months and POD includes peri-procedural (or peri-operative) death at 30-days.

  18. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 6 months (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion occurring within 6 months and POD includes peri-procedural (or peri-operative) death at 30-days.

  19. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 1 year (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion at 1 year and POD includes peri-procedural (or peri-operative) death at 30-days.

  20. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 2 years (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion at 2 years and POD includes peri-procedural (or peri-operative) death at 30-days.

  21. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 3 years (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion at 3 years and POD includes peri-procedural (or peri-operative) death at 30-days.

  22. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 4 years (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion at 4 years and POD includes peri-procedural (or peri-operative) death at 30-days.

  23. Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) [ Time Frame: At 30 days (for POD) and 5 years (for MALE) ]
    MALE includes major amputation or major re-interventions including new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis related to the target lesion at 5 years and POD includes peri-procedural (or peri-operative) death at 30-days.

  24. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 1 month ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  25. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 3 months ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  26. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 6 months ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  27. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 1 year ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  28. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 2 years ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  29. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 3 years ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  30. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 4 years ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  31. Freedom From Major Amputation and Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 5 years ]

    Major amputation will be defined as limb loss at or proximal to the transtibial level. Major amputations will be specified as below-the-knee and above-the-knee amputations.

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  32. Freedom From Above Ankle Amputation [ Time Frame: At 1 month ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  33. Freedom From Above Ankle Amputation [ Time Frame: At 3 months ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  34. Freedom From Above Ankle Amputation [ Time Frame: At 6 months ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  35. Freedom From Above Ankle Amputation [ Time Frame: At 1 year ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  36. Freedom From Above Ankle Amputation [ Time Frame: At 2 years ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  37. Freedom From Above Ankle Amputation [ Time Frame: At 3 years ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  38. Freedom From Above Ankle Amputation [ Time Frame: At 4 years ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  39. Freedom From Above Ankle Amputation [ Time Frame: At 5 years ]
    Freedom From Above Ankle Amputation will be assessed. Amputation will apply only to amputations of the limb that was treated.

  40. Freedom From Restenosis [ Time Frame: At 1 month ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  41. Freedom From Restenosis [ Time Frame: At 3 months ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  42. Freedom From Restenosis [ Time Frame: At 6 months ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  43. Freedom From Restenosis [ Time Frame: At 1 year ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  44. Freedom From Restenosis [ Time Frame: At 2 years ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  45. Freedom From Restenosis [ Time Frame: At 3 years ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  46. Freedom From Restenosis [ Time Frame: At 4 years ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  47. Freedom From Restenosis [ Time Frame: At 5 years ]
    Freedom from re-narrowing of the artery following the alleviation of a previous narrowing, as defined as the presence of a hemodynamically significant restenosis (≥ 50%), which is determined by angiography.

  48. Rate of Binary restenosis [ Time Frame: At 1 month ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  49. Rate of Binary restenosis [ Time Frame: At 3 months ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  50. Rate of Binary restenosis [ Time Frame: At 6 months ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  51. Rate of Binary restenosis [ Time Frame: At 1 year ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  52. Rate of Binary restenosis [ Time Frame: At 2 years ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  53. Rate of Binary restenosis [ Time Frame: At 3 years ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  54. Rate of Binary restenosis [ Time Frame: At 4 years ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  55. Rate of Binary restenosis [ Time Frame: At 5 years ]

    Binary restenosis will be presented as the presence of a hemodynamically significant restenosis ≥ 50% by angiography, or PSVR ≥ 2.4 by duplex ultrasound. In the presence of abnormal reference PSV, the core lab uses the following additional secondary criteria (correlating factors) to identify target lesion stenoses >50% in severity:

    • Focal increase in the absolute PSV at the area of visible plaque
    • Spectral broadening of the waveform at the area of stenosis
    • Post-stenotic turbulence (PST) and/or change in the waveform shape and/or drop in velocity distal to the stenosis
    • Review of the B-mode images for plaque burden

  56. Number of Amputation-free Survival [ Time Frame: At 1 month ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  57. Number of Amputation-free Survival [ Time Frame: At 3 months ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  58. Number of Amputation-free Survival [ Time Frame: At 6 months ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  59. Number of Amputation-free Survival [ Time Frame: At 1 year ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  60. Number of Amputation-free Survival [ Time Frame: At 2 years ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  61. Number of Amputation-free Survival [ Time Frame: At 3 years ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  62. Number of Amputation-free Survival [ Time Frame: At 4 years ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  63. Number of Amputation-free Survival [ Time Frame: At 5 years ]
    Amputation-free survival includes freedom from above ankle amputation and death.

  64. Number of All-cause Death [ Time Frame: At 1 month ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  65. Number of All-cause Death [ Time Frame: At 3 months ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  66. Number of All-cause Death [ Time Frame: At 6 months ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  67. Number of All-cause Death [ Time Frame: At 1 year ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  68. Number of All-cause Death [ Time Frame: At 2 years ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  69. Number of All-cause Death [ Time Frame: At 3 years ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  70. Number of All-cause Death [ Time Frame: At 4 years ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  71. Number of All-cause Death [ Time Frame: At 5 years ]
    All-cause Death composed of cardiac death, vascular death and non-cardiovascular death

  72. Number of Participants with Arterial Thrombosis [ Time Frame: At 1 month ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  73. Number of Participants with Arterial Thrombosis [ Time Frame: At 3 months ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  74. Number of Participants with Arterial Thrombosis [ Time Frame: At 6 months ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  75. Number of Participants with Arterial Thrombosis [ Time Frame: At 1 year ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  76. Number of Participants with Arterial Thrombosis [ Time Frame: At 2 years ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  77. Number of Participants with Arterial Thrombosis [ Time Frame: At 3 years ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  78. Number of Participants with Arterial Thrombosis [ Time Frame: At 4 years ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  79. Number of Participants with Arterial Thrombosis [ Time Frame: At 5 years ]

    Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms.

    • Acute thrombosis: 0 - 24 hours post study procedure
    • Subacute thrombosis: > 24 hours - 30 days post study procedure
    • Late thrombosis: 31 days - 1 year post-procedure
    • Very late thrombosis: > 1 year post-procedure

    Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.


  80. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 1 month ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  81. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 3 months ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  82. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 6 months ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  83. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 1 year ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  84. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 2 years ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  85. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 3 years ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  86. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 4 years ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  87. Number of Participants with Major Re-intervention on index limb [ Time Frame: At 5 years ]
    Major Limb Re-intervention includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization

  88. Primary Assisted Patency [ Time Frame: At 1 month ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  89. Primary Assisted Patency [ Time Frame: At 3 months ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  90. Primary Assisted Patency [ Time Frame: At 6 months ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  91. Primary Assisted Patency [ Time Frame: At 1 year ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  92. Primary Assisted Patency [ Time Frame: At 2 years ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  93. Primary Assisted Patency [ Time Frame: At 3 years ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  94. Primary Assisted Patency [ Time Frame: At 4 years ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  95. Primary Assisted Patency [ Time Frame: At 5 years ]
    Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis

  96. Secondary Patency [ Time Frame: At 1 month ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  97. Secondary Patency [ Time Frame: At 3 months ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  98. Secondary Patency [ Time Frame: At 6 months ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  99. Secondary Patency [ Time Frame: At 1 year ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  100. Secondary Patency [ Time Frame: At 2 years ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  101. Secondary Patency [ Time Frame: At 3 years ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  102. Secondary Patency [ Time Frame: At 4 years ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  103. Secondary Patency [ Time Frame: At 5 years ]
    Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion

  104. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 1 month ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  105. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 3 months ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  106. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 6 months ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  107. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 1 year ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  108. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 2 years ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  109. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 3 years ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  110. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 4 years ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  111. Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: At 5 years ]

    CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography. Bailout with metallic stent, in either study arm, due to acute closure or to achieve < 30% stenosis during index procedure will be considered a CD-TLR.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  112. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 1 month ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  113. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 3 months ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  114. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 6 months ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  115. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 1 year ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  116. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 2 years ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  117. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 3 years ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  118. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 4 years ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  119. Number of Participants with Clinically-driven Target Vessel Revascularization (CD-TVR) [ Time Frame: At 5 years ]

    CD-TVR is the repeat intervention on the target vessel due to recurrent symptoms AND stenosis > 70% by angiography.

    Recurrent symptoms include delayed or worsening wound healing, new or recurrent wound at the treatment site, or worsening Rutherford class.


  120. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 1 month ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  121. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 3 months ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  122. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 6 months ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  123. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 1 year ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  124. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 2 years ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  125. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 3 years ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  126. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 4 years ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  127. Number of Participants with Clinically-driven Target Vessel Revascularization Distal to the Target Lesion [ Time Frame: At 5 years ]
    Clinically-driven Target Vessel Revascularization Distal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue distal to the target lesion

  128. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 1 month ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  129. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 3 months ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  130. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 6 months ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  131. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 1 year ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  132. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 2 years ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  133. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 3 years ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  134. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 4 years ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  135. Number of Participants with Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion [ Time Frame: At 5 years ]
    Clinically-driven Target Vessel Revascularization Proximal to the Target Lesion measures the CD-TVR that occurred at least 5 mm of tissue proximal to the target lesion

  136. Index Wound Assessment for Healing [ Time Frame: At 14 days ]
    Index wound assessment for healing will be assessed by the core laboratory at 14 days

  137. Index Wound Assessment for Healing [ Time Frame: At 30 days ]
    Index wound assessment for healing will be assessed by the core laboratory at 30 days

  138. Index Wound Assessment for Healing [ Time Frame: At 42 days ]
    Index wound assessment for healing will be assessed by the core laboratory at 42 days

  139. Index Wound Assessment for Healing [ Time Frame: At 90 days ]
    Index wound assessment for healing will be assessed by the core laboratory at 90 days

  140. Index Wound Assessment for Healing [ Time Frame: At 180 days ]
    Index wound assessment for healing will be assessed by the core laboratory at 180 days

  141. Index Wound Assessment for Healing [ Time Frame: At 1 year ]
    Index wound assessment for healing will be assessed by the core laboratory at 1 year

  142. Index Wound Assessment for Infection [ Time Frame: At 14 days ]
    Index wound assessment for infection will be assessed by the core laboratory at 14 days.

  143. Index Wound Assessment for Infection [ Time Frame: At 30 days ]
    Index wound assessment for infection will be assessed by the core laboratory at 30 days.

  144. Index Wound Assessment for Infection [ Time Frame: At 42 days ]
    Index wound assessment for infection will be assessed by the core laboratory at 42 days.

  145. Index Wound Assessment for Infection [ Time Frame: At 90 days ]
    Index wound assessment for infection will be assessed by the core laboratory at 90 days.

  146. Index Wound Assessment for Infection [ Time Frame: At 180 days ]
    Index wound assessment for infection will be assessed by the core laboratory at 180 days.

  147. Index Wound Assessment for Infection [ Time Frame: At 1 year ]
    Index wound assessment for infection will be assessed by the core laboratory at 1 year.

  148. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At baseline ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  149. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 1 month ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  150. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 3 months ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  151. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 6 months ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  152. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 1 year ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  153. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 2 years ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  154. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 3 years ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  155. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 4 years ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  156. Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb [ Time Frame: At 5 years ]

    The Rutherford Becker scale is a classification system for claudication and limb ischemia.

    Categories and Clinical Description:

    Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).


  157. Occurrence of new wound [ Time Frame: At 1 month ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  158. Occurrence of new wound [ Time Frame: At 3 months ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  159. Occurrence of new wound [ Time Frame: At 6 months ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  160. Occurrence of new wound [ Time Frame: At 1 year ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  161. Occurrence of new wound [ Time Frame: At 2 years ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  162. Occurrence of new wound [ Time Frame: At 3 years ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  163. Occurrence of new wound [ Time Frame: At 4 years ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  164. Occurrence of new wound [ Time Frame: At 5 years ]
    New wound is defined as wound below the knee in the index limb that was not identified at the time of the index procedure or wound that has recurred in the same location following the healing of the index wound. The new wound will be assessed firstly by the wound assessment core laboratory for etiology. Subsequently, the new wound will be evaluated by the site per protocol until the wound is healed through the 5-year follow-up.

  165. Number of patients with acute limb ischemia [ Time Frame: At 1 month ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  166. Number of patients with acute limb ischemia [ Time Frame: At 3 months ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  167. Number of patients with acute limb ischemia [ Time Frame: At 6 months ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  168. Number of patients with acute limb ischemia [ Time Frame: At 1 year ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  169. Number of patients with acute limb ischemia [ Time Frame: At 2 years ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  170. Number of patients with acute limb ischemia [ Time Frame: At 3 years ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  171. Number of patients with acute limb ischemia [ Time Frame: At 4 years ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  172. Number of patients with acute limb ischemia [ Time Frame: At 5 years ]
    Acute Limb Ischemia is a rapid decrease in lower limb blood flow due to acute occlusion of peripheral artery or bypass graft.

  173. Number of patients with peripheral embolization [ Time Frame: At 1 month ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.

  174. Number of patients with peripheral embolization [ Time Frame: At 3 months ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.

  175. Number of patients with peripheral embolization [ Time Frame: At 6 months ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.

  176. Number of patients with peripheral embolization [ Time Frame: At 1 year ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.

  177. Number of patients with peripheral embolization [ Time Frame: At 2 years ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.

  178. Number of patients with peripheral embolization [ Time Frame: At 3 years ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.

  179. Number of patients with peripheral embolization [ Time Frame: At 4 years ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.

  180. Number of patients with peripheral embolization [ Time Frame: At 5 years ]
    Peripheral embolization refers to the evidence of distal embolization subsequent to the index procedure and peri-procedural period. Signs and symptoms suggest of peripheral embolization may include 1) acute change in vascular exam (sudden onset rest pain, pallor, coolness, or other signs of acute ischemia), 2) petechiae, or 3) sub-ungal hemorrhage.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General Inclusion Criteria:

  1. Subject must provide written informed consent prior to any clinical investigation related procedure.
  2. Subject has symptomatic Critical Limb Ischemia (CLI), Rutherford Becker Clinical Category 4 or 5.
  3. Subject requires primary treatment of up to two de novo or restenotic (treated with prior PTA) infrapopliteal lesions
  4. Subject must be at least 18 years of age.
  5. Female subject of childbearing potential should not be pregnant and must be on birth control.

Note: Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.

Anatomic Inclusion Criteria:

  1. Up to two native infrapopliteal lesions, each lesion located in separate infrapopliteal vessel in the same limb. Restenotic (from prior PTA) lesions are allowed.

    1. Lesion must be located in the proximal 2/3 of native infrapopliteal vessels, with vessel diameter of ≥ 2.5 mm and ≤ 4.00 mm by investigator visual assessment.
    2. Total scaffold length to completely cover/treat a target lesion must not exceed 170 mm (total everolimus drug dose of 1790 µg).
    3. The total scaffold length among all target lesions must not exceed 170 mm.
    4. The target vessel cannot have any other angiographic significant lesions (≥50%).
    5. Tandem lesions are allowed if they are < 3 cm apart and the total scaffold length used to cover the entire diseased segment is ≤ 170 mm. Each tandem lesion is considered one lesion.
  2. Target lesion(s) must have ≥ 70% stenosis, per visual assessment at the time of the procedure. If needed, quantitative imaging (angiography, IVUS, and/or OCT) can be used to aid accurate sizing of the vessels.
  3. The distal margin of the target lesion must be located ≥ 10 cm proximal to the proximal margin of the ankle mortise. The vessel segment distal to the target lesion must be patent all the way to the ankle, with no significant lesion (≥ 50% stenosis).
  4. Significant lesion (≥ 50% stenosis) in the inflow artery(ies) must be treated successfully (as per physician's assessment of the angiography) through standard of care prior to the treatment of the target lesion. Treatment can be done within the same trial procedure
  5. Non-target lesion(s) (if applicable) must be located in separate infrapopliteal vessel(s) from the target lesion, and suitable to be treated per institution standard of care.
  6. Guidewire must cross the target lesion successfully. Crossing in an antegrade fashion is preferred, but retrograde crossing may be used. However, the treatment must be delivered antegrade.

Exclusion Criteria:

General Exclusion Criteria:

  1. Subject is currently participating in another clinical investigation that has not yet completed its primary endpoint.
  2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.
  3. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements.
  4. Incapacitated individuals, defined as persons who are mentally ill, mentally handicapped, or individuals without legal authority, are excluded from the study population.
  5. Subject has had any amputation to the ipsilateral extremity other than the toe or forefoot, or subject has had major amputation to the contralateral extremity < 1 year prior to index procedure and is not independently ambulating.
  6. Subject has known hypersensitivity or contraindication to device material and its degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be adequately pre-medicated.
  7. Subject has known allergic reaction, hypersensitivity or contraindication to aspirin; or to ADP antagonists such clopidogrel, prasugrel or ticagrelor; or to anticoagulants such as heparin or bivalirudin, and therefore cannot be adequately treated with study medications. Subject with planned surgery or procedure necessitating discontinuation of antiplatelet medications, within 12 months after index procedure. Planned amputation that will necessitate discontinuation of antiplatelet medications is allowed.
  8. Subject has life expectancy ≤ 1 year.
  9. Subject has had a stroke within the previous 3 months with residual Rankin score of ≥ 2.
  10. Subject has renal insufficiency as defined as an estimated GFR < 30 ml/min per 1.73m^2.
  11. Subject is currently on dialysis.
  12. Subject has platelet count < 100,000 cells/mm^3 or > 700,000 cells/mm^3, a WBC < 3,000 cells/mm^3, or hemoglobin < 9.0 g/dl.
  13. Subject has known serious immunosuppressive disease (e.g., human immunodeficiency virus), or has severe autoimmune disease, that requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.), or subject is receiving immunosuppression therapy for other conditions. Subjects treated for HIV (Human Immunodeficiency Virus) and who have undetectable viral load, such that their immune system is not considered compromised, are eligible.
  14. Subject has Body Mass Index (BMI) <18.
  15. Subject is receiving or scheduled to receive anticancer therapy for malignancy within 6 months prior to index procedure or within 1 year after the procedure. Patients taking medications classified as chemotherapy but who have been in remission for at least 6 months are eligible.
  16. Subject has coagulation disorder that increases the risk of arterial thrombosis. Subjects with deep vein thrombosis and disorders that increase the risk of deep vein thrombosis can be included in the study.
  17. Subject who requires thrombolysis as a primary treatment modality or requires other treatment for acute limb ischemia of the target limb.
  18. Subject has previously had, or requires surgical revascularization involving any vessel of the ipsilateral extremity. Prior femoropopliteal or aortobifemoral bypass is allowed. Any bypass to the tibial arteries is not allowed.
  19. Subject has signs or symptoms of advanced limb infection or septicemia (fever > 38.5, WBC > 15,000 cells/microliter, hypotension) at the time of assessment. Osteomyelitis of the phalanges or metatarsal heads (as described in exclusion criteria #21a) or cellulitis of the foot amenable to treatment with IV antibiotics at the time of revascularization is acceptable.
  20. Subject is bedridden or unable to walk (with assistance is acceptable). Subjects in wheelchair who are able to mobilize on their own can be enrolled.
  21. Subject with extensive tissue loss salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputations. This includes subjects with:

    1. Osteomyelitis that extends proximal to the metatarsal heads. Osteomyelitis limited to the phalanges or metatarsal heads is acceptable for enrollment.
    2. Gangrene involving the plantar skin of the forefoot, midfoot, or heel
    3. Deep ulcer or large shallow ulcer (> 3 cm) involving the plantar skin of the forefoot, midfoot, or heel
    4. Full thickness heel ulcer with/without calcaneal involvement
    5. Any wound with calcaneal bone involvement
    6. Wounds that are deemed to be neuropathic or non-ischemic in nature
    7. Wounds that would require flap coverage or complex wound management for large soft tissue defect
    8. Full thickness wounds on the dorsum of the foot with exposed tendon or bone.
  22. Subject is unable or unwilling to provide written consent prior to enrollment
  23. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the prior 2 months.

Anatomic Exclusion Criteria:

  1. Lesions with severe calcification, in which there is a high likelihood that successful pre-dilatation cannot be achieved.
  2. Lesion that has prior metallic stent implant.
  3. Significant (≥ 50% stenosis) lesion in a distal outflow artery that would be perfused by the target vessel and that requires treatment at the time of the index procedure.
  4. Subject has had or will require treatment in any vessel with an everolimus drug-coated or drug-eluting device < 30 days pre-study procedure, or during the index procedure, such that the cumulative (Esprit BTK plus everolimus-eluting device) everolimus drug dose exceeds 1790 μg.
  5. Target or (if applicable) non-target vessel contains visible thrombus as indicated in the angiographic images.
  6. Subject has angiographic evidence of thromboembolism or atheroembolism in the ipsilateral extremity. (Pre- and post-angiographic imaging must confirm the absence of emboli in the distal anatomy.)
  7. Unsuccessfully treated proximal inflow limiting arterial stenosis or inflow-limiting arterial lesions left untreated.
  8. No angiographic evidence of a patent pedal artery.
  9. Target or (if applicable) non-target lesion location requiring bifurcation treatment method that requires scaffolding of both branches (provisional treatment, without intention of scaffolding both branches is acceptable).
  10. Aneurysm in the iliac, common femoral, superficial femoral, popliteal or target artery of the ipsilateral extremity.
  11. Visual assessment of the target lesion suggests that the investigator is unable to pre-dilate the lesion according to the vessel diameter.
  12. Target lesion has a high probability that atherectomy will be required at the time of index procedure for treatment of the target vessel.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04227899


Contacts
Layout table for location contacts
Contact: Rhonda Hensley +1 (828) 527-9054 rhonda.hensley@abbott.com
Contact: Karine S Ruster, PhD +1 (408) 845-0764 karine.piard-ruster@abbott.com

Locations
Show Show 56 study locations
Sponsors and Collaborators
Abbott Medical Devices
Investigators
Layout table for investigator information
Principal Investigator: Ramon L Varcoe, MBBS, MS, FRACS, PhD Prince of Wales Private Hospital, Randwick, NSW, Australia
Principal Investigator: Sahil Parikh, MD, FACC, FSCAI New York Presbyterian Hospital, New York, NY
Principal Investigator: Brian DeRubertis, MD, FACS NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY
Layout table for additonal information
Responsible Party: Abbott Medical Devices
ClinicalTrials.gov Identifier: NCT04227899    
Other Study ID Numbers: ABT-CIP-10293
First Posted: January 14, 2020    Key Record Dates
Last Update Posted: May 19, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Abbott Medical Devices:
Infrapopliteal lesions
Esprit BTK Everolimus Eluting Bioresorbable Scaffold System
Percutaneous transluminal angioplasty (PTA)
ABT-CIP-10293
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemia
Pathologic Processes